Figure 5
Bortezomib treatment enhances the sensitivity of patient MM to allogeneic and autologous NK cell–mediated lysis. The patient MM cells were treated with 10 to 50 nM bortezomib for 16 to 24 hours. Treated and untreated cells were then used as targets in a standard 4-hour 51Cr release assay. UPN indicates unique patient number.
